CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 20 enrolled
Drug / intervention
Combination Product (sumatriptan succinate / naproxen sodium) +1 moredrug
Likely dose
RELPAX(eletriptan) 40mg Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00385008
NCT00385008Phase 3Completed
CompareCT.gov

An Open Label, Single Dose, Parallel Group Study to Evaluate Absorption and Transit Characteristics of TREXIMA and RELPAX in Patients Inside and Outside of an Acute Migraine Attack.

GlaxoSmithKline·interventional·Posted Oct 6, 2006·Updated Feb 12, 2018

In Brief

A Phase 3 clinical trial evaluating Combination Product (sumatriptan succinate / naproxen sodium) and RELPAX(eletriptan) 40mg Tablet for Migraine Disorders. Completed, enrolled 20 participants across 1 site.

Detailed Summary

An evaluation of tablet disintegration and absorption and gastric transit of sumatriptan and naproxen sodium from a TREXIMA tablet and eletriptan from a RELPAX 40mg tablet.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Disorders
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 6, 2006
Enrollment StartSep 13, 2006
Primary CompletionNov 24, 2006
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 19.7 years ago

Interventions

Combination Product (sumatriptan succinate / naproxen sodium)drug

sumatriptan/naproxen sodium

RELPAX(eletriptan) 40mg Tabletdrug

eletriptan tablets